scholarly journals An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

2018 ◽  
Vol 184 (2) ◽  
pp. 215-222 ◽  
Author(s):  
David J. Andorsky ◽  
Kathryn S. Kolibaba ◽  
Sarit Assouline ◽  
Andres Forero‐Torres ◽  
Vicky Jones ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
Phase 2 ◽  
Open Label ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial ◽  
Mantle Cell ◽  
Open Label Phase

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

2016 ◽  
Vol 17 (1) ◽  
pp. 48-56 ◽  
Author(s):  
Michael L Wang ◽  
Hun Lee ◽  
Hubert Chuang ◽  
Nicolaus Wagner-Bartak ◽  
Frederick Hagemeister ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Phase 2 ◽  
Single Centre ◽  
Open Label ◽  
Phase 2 Trial ◽  
Mantle Cell ◽  
Open Label Phase

scholarly journals Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial

2018 ◽  
Vol 5 (4) ◽  
pp. e170-e180 ◽  
Author(s):  
Jennifer R Brown ◽  
Mehdi Hamadani ◽  
John Hayslip ◽  
Ann Janssens ◽  
Nina Wagner-Johnston ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Hodgkin Lymphoma ◽  
Lymphocytic Leukaemia ◽  
Phase 2 ◽  
Open Label ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial ◽  
Open Label Phase

scholarly journals Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

2018 ◽  
Vol 5 (3) ◽  
pp. e109-e116 ◽  
Author(s):  
Mats Jerkeman ◽  
Christian Winther Eskelund ◽  
Martin Hutchings ◽  
Riikka Räty ◽  
Karin Fahl Wader ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial ◽  
Mantle Cell

scholarly journals Mantle Cell Lymphoma Mimicking Rectal Carcinoma

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Engin Kelkitli ◽  
Hilmi Atay ◽  
Levent Yıldız ◽  
Ahmet Bektaş ◽  
Mehmet Turgut
Keyword(s):  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Rectal Carcinoma ◽  
Cell Lymphoma ◽  
Treatment Options ◽  
Extranodal Involvement ◽  
Non Hodgkin Lymphoma ◽  
Rectal Involvement ◽  
Mantle Cell ◽  
Rectal Mass

Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma. After the (11;14) translocation was identified as its constant finding in 1992, MCL was recognized as a separate subgroup of non-Hodgkin lymphoma (NHL). In MCL, extranodal involvement may be observed in the bone marrow, the spleen, the liver, and the gastrointestinal system (GIS). Cases of MCL that present with a massive and solitary rectal mass are rare in the literature. In this case report, our aim was to present an MCL patient with a rarely observed solitary rectal involvement mimicking rectal carcinoma and to discuss treatment options for this patient.

scholarly journals Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

2020 ◽  
Vol 7 (7) ◽  
pp. e511-e522 ◽  
Author(s):  
Nagesh Kalakonda ◽  
Marie Maerevoet ◽  
Federica Cavallo ◽  
George Follows ◽  
Andre Goy ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial ◽  
Large B Cell Lymphoma ◽  
Open Label Phase ◽  
Large B Cell

scholarly journals The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Blood ◽  
2011 ◽  
Vol 117 (10) ◽  
pp. 2807-2812 ◽  
Author(s):  
Jonathan W. Friedberg ◽  
Julie M. Vose ◽  
Jennifer L. Kelly ◽  
Faith Young ◽  
Steven H. Bernstein ◽  
...  
Keyword(s):  
Adverse Events ◽  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
Objective Response ◽  
Synergistic Activity ◽  
Significant Activity ◽  
Serious Adverse Events ◽  
Non Hodgkin Lymphoma ◽  
Mantle Cell

AbstractGiven the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequate organ function were treated with bendamustine 90 mg/m2 days 1 and 4; rituximab 375 mg/m2 day 1, and bortezomib 1.3 mg/m2 days 1, 4, 8, 11. Six 28-day cycles were planned. Thirty patients (7 with mantle cell lymphoma) were enrolled and treated. Eight patients experienced serious adverse events, including one event of grade 5 sepsis. Common nonhematologic adverse events were generally grade 1 or grade 2 and included nausea (50%), neuropathy (47%), fatigue (47%), constipation (40%), and fever (40%). Of 29 patients evaluable for efficacy, 24 (83%) achieved an objective response (including 15 with complete response). With median follow-up of 24 months, 2-year progression-free survival is 47% (95% confidence interval, 25%-69%). On the basis of these promising results, the US cooperative groups have initiated randomized trials to evaluate this regimen in follicular and mantle cell lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00547534.

Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

2010 ◽  
Vol 101 (9) ◽  
pp. 2054-2058 ◽  
Author(s):  
Michinori Ogura ◽  
Toshiki Uchida ◽  
Masafumi Taniwaki ◽  
Kiyoshi Ando ◽  
Takashi Watanabe ◽  
...  
Keyword(s):  
Phase I ◽  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Pharmacokinetic Study ◽  
Cell Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Mantle Cell
Sign in / Sign up

Export Citation Format

Share Document